Posted: 31 May 2014 06:07 AM PDT
A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack.
Posted: 30 May 2014 11:24 AM PDT
Among young breast cancer patients, one of the most distressing side effects of chemotherapy is early menopause. But a major study finds the risk of early menopause can be significantly reduced by adding the drug goserelin to the chemotherapy regimen.
|You are subscribed to email updates from All Top News -- ScienceDaily |
To stop receiving these emails, you may unsubscribe now.
|Email delivery powered by Google|
|Google Inc., 20 West Kinzie, Chicago IL USA 60610|